Roche could face competition for Tamiflu in Russia

4 April 2017

Swiss pharma giant Roche (ROG: SIX) may face significant losses in Russia, due to a recent decision of the government to invest funds in the development of a new drug that could be considered as an analogue to Tamiflu (oseltamivir), one of Russia’s best-selling drugs for the treatment of flu.

To date, the government has already invested 33 million roubles (~$590,000) for the development of the new drug and there is a possibility that this sum will be significantly increased, reports The Pharma Letter’s local correspondent.

So far, Roche’s Tamiflu has had no analogues in the Russian market, however there is a possibility that such a situation will change already next year. The development of the new drug will be finally completed by the end of next year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK